Safety and Effects of Ramipril Combined With Candesartan
Information source: Gachon University Gil Medical Center
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: ramipril, candesartan (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Gachon University Gil Medical Center Official(s) and/or principal investigator(s):
Kwang K Koh, MD, Principal Investigator, Affiliation: Cardiology, Gil Heart Center, Gachon Medical School
Summary
we hypothesized that combination therapy has additive beneficial effects to improve
endothelial dysfunction and adipocytokine profiles in patients with hypertension.
Clinical Details
Official title: Cardiovascular and Metabolic Effects of Combination Therapy With Ramipril and Candesartan In Hypertensive Patients
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Primary outcome: comparison of endothelium-dependent dilation among the 3 treatment schemes
Detailed description:
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16
mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled
cross-over trial with three treatment arms and two washout periods (each 2 months).
Eligibility
Minimum age: 35 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients with mild to moderate hypertension
Exclusion Criteria:
- We will exclude patients with severe hypertension, unstable angina, acute myocardial
infarction, or renal insufficiency.
Locations and Contacts
Additional Information
Starting date: August 2003
Ending date: March 2006
Last updated: July 25, 2006
|
